NCT06489652View on ClinicalTrials.gov

89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2027

Conditions
Systemic Sclerosis
Interventions
DRUG

89Zr-Oxine-RY_SW01 Cell Injection

Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY\_SW01 cells injection

All Listed Sponsors
lead

Jiangsu Renocell Biotech Company

INDUSTRY

NCT06489652 - 89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis | Biotech Hunter | Biotech Hunter